Combination Therapies Targeting HDAC and IKK in Solid Tumors.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Histone deacetylase inhibitors (HDACi) are effective in hematological cancers but show limited success in solid tumors.
• HDACi can paradoxically promote tumor cell proliferation in solid tumors via induction of chemokines like IL-8 (CXCL8).
• This effect is mediated by the IκB kinase (IKK) pathway, counteracting the intended anticancer effects of HDACi.

Purpose of the Study:

• To elucidate the mechanisms underlying HDAC inhibitor-induced CXCL8 expression in solid tumors.
• To explore the potential of combination therapies targeting both HDACs and IKK for solid tumor treatment.

Main Methods:

• Discussion of recent studies and proposed mechanisms.
• Analysis of signaling pathways involved in HDACi response.
• Review of potential therapeutic strategies.

Main Results:

• Class I HDAC inhibitors induce IKK-dependent expression of CXCL8.
• CXCL8 promotes tumor cell proliferation, limiting HDACi efficacy in solid tumors.
• Targeting both HDACs and IKK presents a promising therapeutic avenue.

Conclusions:

• Understanding HDACi-induced CXCL8 is crucial for overcoming therapeutic limitations in solid tumors.
• Combination therapies targeting HDACs and IKK offer a strategy to enhance anticancer efficacy.